03-Jun-2021 - Lonza Group Ltd

Lonza and Moderna Announce Further Collaboration For Drug Substance Manufacturing of COVID-19 Vaccine Moderna in the Netherlands

Lonza announced the expansion of its collaboration with Moderna. The expanded collaboration will further extend the manufacture of the drug substance for the COVID-19 Vaccine Moderna and provides for the installation of a new manufacturing line for drug substance production at Lonza’s Geleen (NL) site.

The new production line in Geleen (NL) will complement Lonza’s existing drug substance production network for COVID-19 Vaccine Moderna and deliver a crucial manufacturing step to increase overall drug substance output. As such, the new production line will contribute to the supply of up to an additional 300 million doses per year, at a 50ug dose, once operating at full capacity.

In May 2020, Lonza and Moderna announced a ten-year strategic collaboration agreement to enable the manufacture of Moderna’s COVID-19 vaccine and additional Moderna products in the future. Since then, Lonza has installed three production lines at its Visp (CH) site and one production line in Portsmouth (US). In April 2021, Lonza and Moderna entered a new agreement to add three further production lines at its Visp (CH) site.

The new production line in Geleen (NL) is expected to be operational by the end of 2021. Lonza will leverage its existing infrastructure in Geleen (NL) to provide fast build-out and ramp-up of operations.

Facts, background information, dossiers
More about Lonza
  • News

    Lonza Invests CHF 20 million to Expand API Development and Manufacturing Facility in Nansha, China

    Lonza today announced new investments in GMP laboratories and mid-scale manufacturing assets at its API manufacturing center in Nansha, China. The investments, totaling over CHF 20 million, will allow Lonza to provide a smoother transition from small-scale to large-scale manufacturing for c ... more

    Lonza and Moderna Enter New Agreement to Double Drug Substance Production for COVID-19 Vaccine in Visp

    Lonza announced the expansion of its collaboration with Moderna, a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, to manufacture the drug substance for the COVID-19 Vaccine Moderna. The expanded collaboration provides for the installation of three additiona ... more

    CEO Marc Funk leaves Lonza

    Lonza announced that Marc Funk, CEO, will leave the Company for personal reasons. The Board of Directors also announced that Albert Baehny, Chairman, will take on the additional responsibility of Chief Executive Officer on an ad interim basis until a permanent successor is found. Marc will ... more

  • Companies

    Lonza Cologne GmbH

    About Lonza Cologne GmbH Lonza Cologne GmbH offers products for various everyday uses, such as disinfectants and detergents in hospitals or pool and spa areas, in pesticides against snails (metaldehyde), in sports and energy drinks (vitamin B3, L-Carnitine) or in body lotions as emulsifyin ... more

    Lonza Group Ltd

    Lonza continues to leverage its core strengths in innovation, technology, and regulatory expertise while capturing cross-divisional synergies in manufacturing, research, and sales. By clicking the Factsheet will find a detailed breakdown of our management committees, business divisions, gro ... more

    Lonza Milano, S.r.l.

    more

More about Moderna Therapeutics